CONVENTIONAL treatment of patients with dilated cardiomyopathy has focused on the use of diuretic, inotropic, and vasodilator drugs. Despite the development of new vasodilators and inotropic agents, the bleak prognosis for these patients has changed little. An innovative and somewhat radical approach to the therapy of dilated cardiomyopathy was reported in 1975 by Waagstein et al. l in Goteborg, Sweden. These investigators described seven patients with dilated cardiomyopathy who responded to,3-adrenergic-blocking drugs with marked clinical improvement over a period of several months.
Since 1975 several groups of investigators have studied the effects of 8-adrenergic blockers on the hemodynamics, clinical course, and survival of patients with dilated cardiomyopathy. Despite a widespread belief by the medical community that /3-adrenergic blockers are harmful to patients with congestive heart failure, several studies have reported a salutary effect of these drugs in patients with idiopathic dilated cardiomyopathy. The results of published studies on this subject have been inconsistent, however.
The evidence in favor
In the initial study by Waagstein et al. ,' seven patients with advanced idiopathic dilated cardiomyopathy were treated with /3-adrenergic blockade for 2 to 12 months. All patients had resting tachycardia, with a mean heart rate (98 + 13 beats/min) that fell to 69 ± 16 beats/min at an average of 5.4 months of f3-blockade. All patients experienced improvement in symptoms -four immediately and three graduallyafter 1 month of therapy. Resolution of peripheral edema and ascites was also noted, and allowed reduction of doses of diuretics given to these patients. There was improvement in exercise capacity (seven of seven pa-tients) and an increase in left ventricular ejection time and velocity of circumferential fiber shortening.
As a pilot study, this investigation was quite provocative. Contrary to the deterioration expected in these seven patients, functional class improved, physical working capacity was increased, and noninvasive parameters of myocardial function suggested improved ventricular performance.
In 1979 the same group of investigators2 reported that the survival of 24 patients with dilated cardiomyopathy treated with /3-blocking drugs was prolonged compared with that of a control group selected retrospectively. Further describing their experience, the Swedish group reported in 1980 to 1983 on an expanding cohort of patients with dilated cardiomyopathy studied in a nonrandomized fashion.3-5 In one study4 they examined the effects of withdrawal of ,3-adrenergic blockers in 15 patients who had improved on therapy with metoprolol. After discontinuation of metoprolol, six patients developed exacerbation of left and right heart failure within 2 to 14 days. Thirteen patients exhibited a fall in left ventricular ejection fraction (determined echocardiographically), with an overall decrease of from 0.46 + 0.03 to 0.35 ± 0.03 (p < .01). All but one patient showed an increase in heart rate after withdrawal of metoprolol. By 1983, the Swedish group had entered 46 patients into their study, and the average follow-up time had been increased to 34 months (22 days to 110 months).5 Eighteen of the subjects that entered the study more recently underwent cardiac catheterization and endomyocardial biopsy before treatment with ,8-blockers and were given 15 mg iv metoprolol over a short term. All but one, patient tolerated this dose. The findings from short-and longterm studies5 in these patients are summarized in figure   1 . Cardiac index fell acutely with the initiation of /3-blockade (2.2 ± 0.5 to 1.9 ± 0.5 liters/min/m2), but six patients in whom cardiac index was measured during long-term therapy showed an increase in cardiac index (1. 8 ± 0.7 to 2.5 ± 0.6 liters/min/m2). Similar that results in a decrease in myocardial energy demand, "allowing more energy to be used for the contractile work." This proposed mechanism may be playing some role, but major improvement in contractile function is not seen over the short term, despite an immediate reduction in heart rate. However, increased myocardial energy stores may renew a favorable balance between cellular reparative and synthetic processes on the one hand, and degenerative and catabolic processes on the other, thus permitting a gradual and progressive improvement in cellular structure and function. In this regard, a recent report'2 described a reversible form of left ventricular dysfunction in patients with chronic, uncontrolled, symptomatic tachycardia. After tachyarrhythmias were stopped with a corrective procedure, patients experienced marked improvement in left ventricular ejection fraction, as determined by radionuclide ventriculography, from 0.19 856 ± 0.09 at baseline to 0.44 + 0.14 at 11 to 51 months after surgery (p < .005). /3-Adrenergic blockade may similarly improve left ventricular function in patients with cardiomyopathy and resting tachycardia.
Several investigators studying diastolic function have noted the deleterious physiologic effects of tachycardia in patients with dilated cardiomyopathy. Braunwald et al. 13 found that "tachycardia above a rate critical for each heart elevated left ventricular end-diastolic pressure for any given end-diastolic circumference." Mitchell et al. ' 4 demonstrated that "abbreviation of diastole at high imposed heart rates . . . may leave an inadequate time for ventricular relaxation to take place and for inertial and viscous factors to be dissipated." In a hemodynamic study of patients with congestive cardiomyopathy, Grossman et al. '5 demonstrated impaired left ventricular relaxation (decreased peak negative dP/dt, depressed rate of early diastolic circumferential fiber lengthening) and decreased diastolic chamber distensibility. Indexes of left ventricular contractility and relaxation were depressed in patients at rest and failed to be augmented normally with pacinginduced tachycardia (figure 2). It was suggested in that study that the inability to increase the rates of left ventricular contraction and relaxation during tachycardia may be secondary to either alterations in wall viscoelasticity or to a biochemical effect such as defective calcium release and uptake.
Another possible mechanism of the beneficial effect of /3-blockade in patients with dilated cardiomyopathy is the reduction in afterload yielded by inhibition of the sympathetically mediated increase in vasomotor tone 15) present in these patients (via stimulation of prostaglandins or reduction of renin release). Other speculation has focused on the protective action of f-blockade against the possible deleterious effects of sympathetic activity on the myocardium. Fleckenstein et al. 16 demonstrated that high concentrations of isoproterenol led to excess calcium entry into cells, causing overactivation of calcium-dependent intracellular ATPases, resulting in energy depletion, mitochondrial damage, and cell necrosis. This effect was prevented by fl-blocking drugs. Bajusz et al. 17 demonstrated acceleration of the natural course of disease in Syrian hamsters with hereditary cardiomyopathy by the administration of catecholamines, an effect that could be inhibited by fl-blockers. In man, pheochromocytoma may induce cardiomyopathy, and fl-blockade has been used to protect the myocardium in patients with this disorder.
Finally, there is evidence that fi-adrenergic receptors are down-regulated in patients with congestive heart failure,18 and that myocardial catecholamine levels are depleted even though serum levels are high. fiBlockade may permit up-regulation of receptors,9 allowing for restoration of cardiac norepinephrine and improved myocardial function.
In conclusion, the treatment of patients with dilated cardiomyopathy and congestive heart failure with fiadrenergic blocking drugs remains controversial and awaits ultimate support or discredit by a large, randomized, double-blind controlled trial in which diagnostic entry criteria, type and dose of fl-blocker used, and follow-up regimen are standardized. However, it appears likely that a subpopulation of patients with dilated cardiomyopathy does respond dramatically to this therapy with symptomatic and functional improvement and prolonged life. The characteristics that define this subpopulation need to be identified. fi-Adrenergic-blocking drugs will not be a panacea for congestive heart failure resulting from dilated cardiomyopathy, but may well be an important adjunct in the treatment of many patients with this condition.
